NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus”), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announced the additional sale of approximately $3.4 million in aggregate principal amount of convertible promissory notes and accompanying warrants. Together with a prior sale of $2.3 million of convertible promissory notes and accompanying warrants, the Company raised an aggregate of $5.7 m ...

NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. ROUYN-NORANDA, Quebec, June 18, 2025 (GLOBE NEWSWIRE) -- Abcourt Mines Inc. ("Abcourt" or the "Corporation") (TSX Venture: ABI) (OTCQB: ABMBF) is pleased to announce that it intends to complete a non-brokered private placement of a secured convertible debenture of the Corporation (the "Debenture") for gross proceeds of $3,000,000 (the "Debenture Offering"). Debenture Offering Concurrently with the closing of the Debenture ...

Core Viewpoint - Goliath Resources Limited has amended the exercise price of common share purchase warrants related to its recent private placements, which include a "bought deal" offering and a concurrent offering, with the new exercise price set at C$2.12 per share [4]. Group 1: Offerings and Financial Details - The Company is conducting a "bought deal" private placement of 6,310,000 common shares at a price of C$3.17 per share, aiming for gross proceeds of C$20,002,700 [1]. - A concurrent offering of up to 1,281,545 Charity Flow-Through Shares is also being conducted at the same price of C$3.17 per share, targeting gross proceeds of up to C$4,062,500 [1]. - The Underwriters will receive a cash commission of 6.0% of the gross proceeds from the Bought Deal Offering and warrants equal to 6.0% of the shares sold [2]. - Finders involved in the Concurrent Offering will receive a similar compensation structure, including a cash fee of 6.0% and warrants [3]. Group 2: Amendments and Regulatory Approvals - The exercise price for both the Broker Warrants and Finder's Warrants has been amended from C$1.95 to C$2.12 per common share, while other terms remain unchanged [4]. - The closing of both the Bought Deal Offering and the Concurrent Offering is subject to regulatory approvals, including that of the TSX Venture Exchange [5]. Group 3: Company Background - Goliath Resources Limited is focused on exploring precious metals projects in the Golden Triangle of northwestern British Columbia, with all projects located in favorable geological and geopolitical settings [7]. - The Company has strategic cornerstone shareholders, including Crescat Capital and McEwen Mining Inc., indicating strong backing in the industry [7].

Core Points - Beauce Gold Fields has received Board approval to extend the exercise date of 6,000,000 outstanding common share purchase warrants until June 14, 2027 [1][2] - The warrants, originally set to expire on June 15, 2025, have an exercise price of $0.10, and none have been exercised to date [2] Company Overview - Beauce Gold Fields is focused on exploring and developing the largest placer gold district in eastern North America, with the goal of tracing old placer gold workings back to a bedrock source to uncover economic lode gold deposits [3] - The flagship property is the St-Simon-les-Mines Gold project, which is historically significant as the site of Canada's first gold rush, predating the Yukon Klondike [3] - The Beauce region has a rich history of placer gold mining, with operations from the 1860s to the 1960s, producing some of the largest gold nuggets in Canadian mining history, ranging from 50 ounces to 71 ounces [3] - The company is currently exploring recently discovered antiform systems that may have contributed to extensive auriferous placer deposits in Beauce [3] - The geological model suggests that placer gold formed in stressed quartz pockets within layered domed Axis of Antiforms, similar to notable global Saddle Reef formations [3]

Core Viewpoint - Altisource Portfolio Solutions S.A. has announced the approval and upcoming trading of two types of warrants on the Nasdaq Global Select Market, which are expected to provide investment opportunities for stakeholders [1]. Group 1: Warrants Overview - The company has distributed two types of warrants: Cash Exercise Stakeholder Warrants and Net Settle Stakeholder Warrants, which will trade under the tickers "ASPSZ" and "ASPSW" respectively [1]. - Each warrant allows the holder to purchase 1.625 shares of common stock at an exercise price of $1.95 per warrant, initially equivalent to $1.20 per share [2]. - The Cash Exercise Stakeholder Warrants will expire on April 2, 2029, while the Net Settle Stakeholder Warrants will expire on April 30, 2032 [3]. Group 2: Exercise Conditions - Warrants can be exercised starting from July 2, 2025, or the first date when the volume-weighted average price (VWAP) of the common stock meets or exceeds the implied per share exercise price of $1.20 for fifteen consecutive trading days [2]. - The company will not issue fractional shares upon exercise; any fractional shares will be rounded down to the nearest whole number [2]. Group 3: Company Background - Altisource Portfolio Solutions S.A. is a leading integrated service provider and marketplace for the real estate and mortgage industries, focusing on operational excellence and innovative services [7].

Core Points - Opus One Gold Corporation closed a second and final tranche of its non-brokered private placement of flow-through shares and units, raising aggregate gross proceeds of $578,450.25 on April 25, 2025 [1] - The total issuance included 5,353,850 flow-through shares at $0.065 each and 4,190,000 units at $0.055 each, with each unit consisting of one common share and one warrant [2] - The overall gross proceeds from both tranches amounted to $1,545,700.30, with funds allocated for exploration on mineral properties and general working capital [3] Financial Details - The company issued a total of 20,234,620 flow-through shares and 4,190,000 units across both tranches [3] - Cash finders fees amounted to $26,150, and a total of 369,230 compensation warrants were issued, each exercisable at $0.10 for 24 months [5] - Previous private placement details included 995,636 finders' warrants and $101,460 in cash finders' fees [6] Regulatory and Compliance - The offering was conducted under the "accredited investor" exemption in Canada, with a four-month hold period applicable to the securities issued [4] - Closing of the offering is subject to approval from the TSX Venture Exchange and customary closing conditions [5] Company Overview - Opus One Gold Corporation focuses on discovering high-quality gold and base metals deposits in the Abitibi Greenstone Belt, a prolific mining area [8]

DXS INTERNATIONAL PLC (AQSE: DXSP) Granting of Share Options and Warrants The Board of DXS International plc (the “Company” or “DXSP), the AQSE Growth Market quoted clinical decision support developer and supplier of clinical decision support systems, announces that it yesterday granted share options to a number of directors, employees, and consultants. Most of these options grants are under an Enterprise Management Incentive (“EMI”) scheme and the remainder under an unapproved share option scheme. All thes ...

Core Viewpoint - BioPorto A/S has issued 1,700,000 warrants to its Board of Directors as part of their remuneration, with each warrant allowing the purchase of one share at an exercise price of DKK 1.50, reflecting the current closing price on Nasdaq Copenhagen [1][2]. Summary by Sections Warrants Issuance - The issuance of warrants was approved during the annual general meeting on April 11, 2025, and is part of the company's compensation strategy for its Board members [1]. - The warrants will vest in equal tranches quarterly over a two-year period, with the first tranche becoming available at the start of the first calendar quarter following the grant date [3]. Terms and Conditions - The warrants are governed by the company's incentive warrant program and include provisions for claw-back in cases of erroneous financial information and accelerated vesting in the event of a takeover or business combination [4]. - The theoretical market value of the newly issued warrants is calculated to be DKK 1,843,580, based on the Black-Scholes formula, with an interest rate of 2.37% and historical volatility of 63.82% over 120 months [5]. Company Overview - BioPorto specializes in in vitro diagnostics, focusing on actionable biomarkers to enhance patient management and improve clinical outcomes [7]. - The company's flagship products utilize the NGAL biomarker to assist in the risk assessment and diagnosis of Acute Kidney Injury (AKI), enabling faster identification and intervention for at-risk patients [8]. - BioPorto operates facilities in Copenhagen, Denmark, and Boston, MA, USA, and is listed on the Nasdaq Copenhagen stock exchange [9].